Effect of Acetazolamide and Zoledronate on Simulated High Altitude-Induced Bone Loss

Mikkel Bo Brent*, Ulf Simonsen, Jesper Skovhus Thomsen† and Annemarie Brüel†

Department of Biomedicine, Aarhus University, Aarhus, Denmark

Exposure to hypobaric hypoxia at high altitude puts mountaineers at risk of acute mountain sickness. The carbonic anhydrase inhibitor acetazolamide is used to accelerate acclimatization, when it is not feasible to make a controlled and slow ascend. Studies in rodents have suggested that exposure to hypobaric hypoxia deteriorates bone integrity and reduces bone strength. The study investigated the effect of treatment with acetazolamide and the bisphosphonate, zoledronate, on the skeletal effects of exposure to hypobaric hypoxia. Eighty 16-week-old female RjOrl : SWISS mice were divided into five groups: 1. Baseline; 2. Normobaric; 3. Hypobaric hypoxia; 4. Hypobaric hypoxia + acetazolamide, and 5. Hypobaric hypoxia + zoledronate. Acetazolamide was administered in the drinking water (62 mg/kg/day) for four weeks, and zoledronate (100 mg/kg) was administered as a single subcutaneous injection at study start. Exposure to hypobaric hypoxia significantly increased lung wet weight and decreased femoral cortical thickness. Trabecular bone was spared from the detrimental effects of hypobaric hypoxia, although a trend towards reduced bone volume fraction was found at the L4 vertebral body. Treatment with acetazolamide did not have any negative skeletal effects, but could not mitigate the altitude-induced bone loss. Zoledronate was able to prevent the altitude-induced reduction in cortical thickness. In conclusion, simulated high altitude affected primarily cortical bone, whereas trabecular bone was spared. Only treatment with zoledronate prevented the altitude-induced cortical bone loss. The study provides preclinical support for future studies of zoledronate as a potential pharmacological countermeasure for altitude-related bone loss.

Keywords: diamox, high altitude, bone strength, bone loss, mountaineering

1 INTRODUCTION

Prolonged exposure to high altitude environments, i.e. above 2,500 to 3,000 meters, can result in acute mountain sickness (AMS). The risk of developing AMS is notably higher when mountaineers ascend rapidly without sufficient time for acclimatization to the diminished inspiratory oxygen pressure. The initial symptoms of AMS are headache, loss of appetite, fatigue, peripheral edema, sleep apnea, and general malaise (1). Although the initial symptoms of AMS are relatively mild, it may progress to life-threatening high altitude pulmonary edema (HAPE) (2) or high altitude cerebral edema (HACE) (3). Studies in rodents have suggested that exposure to high-altitude environments may affect the...
musculoskeletal system by reducing bone strength and inducing muscle atrophy (4, 5). However, observational follow-up studies in mountaineers are sparse, and only one study has measured bone mineral density (BMD) before and after expeditions to summit either Si Guang Feng (7,308 m) or Xixabangma (8,027 m). The study reported decreased BMD at the distal radius immediately after the expedition was completed, which was not fully recovered 12 months after returning to a habitual ambient pressure (6).

Several pharmaceutical countermeasures are routinely used to prevent or treat AMS (7). The Wilderness Medical Society recommends acetazolamide and dexamethasone to prevent AMS, although only acetazolamide facilitates acclimatization (8). Acetazolamide is a carbonic anhydrase inhibitor that causes bicarbonate diuresis, respiratory stimulation, and decreases cerebrospinal fluid production, and its effectiveness in the prevention of AMS has been established in multiple trials (9–12). Treatment of high altitude-related illnesses has previously mainly focused on pharmaceutical countermeasures against AMS, HAPE, and HACE, whereas treatments targeting the altitude-related deterioration in bone integrity is still uncharted territory.

Carbonic anhydrase is a family of enzymes that catalyze the interconversion between carbonic dioxide and water and the dissociated ions of carbonic acid (13) and is expressed in various cells, including osteoclasts (14). Osteoclasts use the cytosolic carbonic anhydrase II to produce protons that are transported through their ruffled border by H+-ATPases enabling intense acidification of the subjacent bone resorption pit (15). The acidification of the resorption pit is crucial to initiate inorganic mineral dissolution and successful bone resorption.

The effect of acetazolamide has previously been studied in bone cells (16, 17), as treatment for denervation-induced bone loss in rats (18), or to counteract post-menopausal osteoporosis in women (19), where it has been able to inhibit osteoclastic bone resorption and preserve bone mass. Still, to our knowledge, no study has investigated the skeletal effects of acetazolamide in rodents exposed to simulated high altitude or mountaineers participating in high altitude expeditions. Considering the crucial role of carbonic anhydrase to normal osteoclastic function and bone resorption, treatment with acetazolamide as a countermeasure against AMS might therefore have a pleasant side effect of mitigating altitude-induced bone loss. Knowledge of effective pharmacological countermeasures of bone loss is warranted since an increasing number of mountaineers are attempting to summit the highest mountains on earth each year, and many climbers are in their fifties or sixties (20, 21).

In the present study, we investigate whether treatment with acetazolamide alleviates the skeletal effects of exposure to simulated high altitude. In addition, the effect of acetazolamide is compared to that of the bisphosphonate zoledronate, which is currently the first-line therapy for most patients with osteoporosis (22).

2 MATERIAL AND METHODS

The study comprised eighty 16-week-old female mice (RjOrl : SWISS) purchased from Janvier Labs (Le Genest-Saint-Isle, France). At arrival the mice had a mean body weight of 34.8 ± 2.6 g. The animals were housed groupwise (n = 6/cage) at the animal facility at Aarhus University, Denmark at a constant temperature of 20°C and computer-controlled light/dark cycle (12/12 h). All cages were standard plastic cages (1290D, Eurostandard Type III, Tecniplast, Milan, Italy) with a floor area of 820 cm² (425 mm × 266 mm × 155 mm), equipped with rodent nesting material made of kraft paper (Sizzle Nest, Datesand, UK), play tunnels, and wood gnawing blocks. During the study, all mice had unrestricted access to standard pelleted rodent chow and tap water (1324 maintenance diet for rats and mice, Altromin, Lage, Germany). Seven days before study start, the mice were stratified according to their body weight into five groups (n = 16/group): 1. Baseline; 2. Normobaric (Normo); 3. Hypobaric hypoxia (Hypo); 4. Hypobaric hypoxia + acetazolamide (Hypo + AZ), and 5. Hypobaric hypoxia + zoledronate (Hypo + ZOL).

Acetazolamide (A6011, Sigma-Aldrich, St. Louis, MO, USA) was mixed with the drinking water, and 2% sucrose was added (145 mg acetazolamide/liter) before the solution was filled into custom-made light-shielded black drinking bottles. Chow consumption and water intake was monitored weekly, and the concentration of acetazolamide in the drinking water was adjusted to ensure a target dose of approximately 50 mg/kg/day. Acetazolamide was administered until the end of the study. Only animals treated with acetazolamide received sucrose in their drinking water to encourage consumption. Zoledronate (100 μg/kg, Fresenius Kabi, Bad Homburg vor der Höhe, Germany) was injected subcutaneously (s.c.) once at the study start.

Mice allocated to hypobaric hypoxia were housed at 500 mbar (corresponding to an altitude of 5,500 m or approximately the barometric pressure at Mount Everest Base Camp), whereas mice in the Normobaric group were housed at sea level atmospheric pressure (Figure 1A). The hypobaric environment was only interrupted for one hour once weekly for cleaning and replacing water and chow. Mice allocated to hypobaric hypoxia were acclimatized for three days before study start, to enable a gradual adaptation to the lower ambient pressure. The animal model of hypobaric hypoxia has previously been used and described in detail (5).

In order to assess bone formation throughout the study, all animals except the Baseline group, were injected s.c. with tetracycline (20 mg/kg, T3383, Sigma-Aldrich, St. Louis, MO, USA) and alizarin (20 mg/kg, A3882, Sigma-Aldrich, St. Louis, MO, USA) one and two weeks before sacrifice, respectively.

Mice allocated to the Baseline group were sacrificed at study start to establish the skeletal status at baseline, while the remaining mice were sacrificed after four weeks (5). All mice were sacrificed under general anesthesia by inhalation of isoflurane (Attane Vet, ScanVet, Fredensborg, Denmark), and immediately thereafter, tissue was extracted. One mouse allocated to the Normobaric group and one to the Hypobaric group died unexpectedly before the study finished.

All animal procedures were approved by the Danish Animal Experiment Inspectorate (2018–15–0201–01436) and reported
Both femora, tibia, and L4 vertebra were isolated and any remaining soft tissue were carefully removed. The right femur and tibia and L4 were stored in Ringer’s solution at −20°C, while the left femur was immersion-fixed in 0.1 M sodium phosphate-buffered formaldehyde (4% formaldehyde, pH 7.0) for 48 h and then stored in 70% ethanol (5). Bone lengths of the right femur and tibia were determined using a digital sliding caliper.

2.2 Whole Muscle and Muscle Cell Cross-Sectional Area

The rectus femoris muscles were halved at the midpoint, placed on a flat-bed image scanner (Perfection 3200 Photo; Seiko Epson, Nagano, Japan), and scanned at 300 DPI to determine the whole muscle cross-sectional area (CSA) (28). CSA was estimated in Adobe Photoshop 2021 (San Jose, California, USA) by contouring the muscle CSA.

The halved rectus femoris muscle was then immersion-fixed in 0.1 M sodium phosphate-buffered formaldehyde (4% formaldehyde, pH 7.0) and embedded in plastic-based 2-hydroxyethyl methacrylate (Technovit 7100, Heraeus Kulzer, Wehrheim, Germany). On a microtome (Jung RM2065; Leica Instruments, Nussloch, Germany), the embedded muscles were cut into 2-µm-thick sections and stained with Masson’s trichrome. The sections were used to determine myofiber CSA using a light microscope (Nikon Eclipse i80, Tokyo, Japan) at a final magnification of ×1190 (29). On average, 234 myofiber profiles were counted per sample to determine the average myofiber CSA.

2.3 Hematocrit

Blood was collected in microcapillary tubes and centrifuged (iFuge HCT, Neuation, Gujarat, India) at 14,000 relative centrifugal force (RCF) for 5 min. Then, the hematocrit was estimated using a manual microhematocrit reader as previously described (5).

2.4 Dual-Energy X-ray Absorptiometry

In order to determine areal bone mineral density (aBMD) and bone mineral content (BMC), the right femur and tibia were scanned by dual-energy X-ray absorptiometry (DXA) (pDEXA Sabre XI; Norland Stratec, Pforzheim, Germany) at a pixel size of 0.1 mm × 0.1 mm and a scan speed of 3.0 mm/s (5).

2.5 Micro Computed Tomography

Trabecular microstructure and cortical morphology were analyzed using a desktop micro computed tomography (µCT) scanner (Scanco µCT 35, Scanco Medical AG, Bruttisellen, Switzerland) (Figure 2). The distal femoral metaphysis, femoral epiphysis, femoral mid-diaphysis, and L4 were scanned in high-resolution mode (1000 projections/180°), at an isotropic voxel size of 3.5 µm, an X-ray tube voltage of 55 kVp, a current of 145 μA, and an integration time of 800 ms. Beam hardening effects were reduced using a 0.5 mm aluminum filter (5, 30).

The distal femoral metaphysis was analyzed using a 1000-µm-high volume of interest (VOI), the femoral epiphysyal VOI was approximately 330-µm-high, and L4 was analyzed using an approximately 3,000-µm-high VOI. All these VOIs contained
The cortical bone of the femoral mid-diaphysis was analyzed using in-house developed software. A Gaussian filter (σ = 0.8 and support = 1) were used to low-pass filter the 3D data and segmentation was conducted using a global fixed threshold filter of 548 mg HA/cm³.

### 2.6 Mechanical Testing

Bone strengths of the femoral mid-diaphysis, femoral neck, and vertebral body of L4 were determined using a material testing machine (Instron model 5566, United Kingdom) as previously described (27). Embedded undecalciﬁed in methyl methacrylate (MMA), the distal part of the left femur was cut in 7-µm-thick longitudinal sections on a microtome (Jung RM2065; Leica Instruments, Nussloch, Germany). The sections were either left unstained for dynamic bone histomorphometry, stained with Masson Goldner trichrome to assess osteoblast and osteoid-covered surfaces, or stained for tartrate-resistant acid phosphatase (TRAP) and counterstained with aniline blue to detect osteoclasts (33). A microscope (Nikon Eclipse i80, Tokyo, Japan) able to project live images to a computer equipped with the Visiopharm stereology software was used for the histological assessment. All histological assessments using optical microscopy were conducted at a final magnification of ×1190 and the ﬁelds of view for longitudinal sections were sampled covering 100% of the region of interest (ROI).

### 2.8 Dynamic Bone Histomorphometry

The unstained sections of the left distal femoral metaphysis and right femoral mid-diaphysis were stained for dynamic bone histomorphometry to determine mineralizing surfaces (MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS) as previously described (5, 30). An imputed value of zero was used for MAR in case of no double labels (34). MS/BS, MAR, and BFR/BS were quantiﬁed and calculated in accordance with the current ASBMR Histomorphometry Nomenclature Committee guideline (34).

For the femoral mid-diaphysis, labels at the periosteal and endocortical bone surface were counted using a 24-arm radiating grid. For the distal femoral metaphysis, a 1000-µm-high ROI was delineated along the endocortical edge starting 300 µm above the growth plate, containing trabecular bone only (5, 30).

### 2.9 Bone Cells

The Masson-Goldner trichrome-stained sections of the left femoral metaphysis were used to estimate osteoblast-covered surfaces (ObS/BS) and osteoid-covered surfaces (OS/BS). Osteoblasts were deﬁned as cuboidal cells with a single nucleus residing on an intact bone surface. Osteoid were deﬁned as the red unmineralized matrix at the very edge of the bone surface. The sections of the left femoral metaphysis stained for TRAP were used to estimate osteoclast-covered surfaces (OcS/BS). Osteoclasts were deﬁned as multinucleated TRAP-positive cells residing on an intact bone surface (34). Osteoblasts, osteoid, and osteoclasts were estimated using a 1000-µm-high ROI starting 300 µm above the growth plate, containing trabecular bone only (5).

### 2.10 Statistics

Data were analyzed using GraphPad Prism 9.1.1. (GraphPad Software, San Diego, CA, USA). Normality of data were assessed using visual inspection of Q-Q plots and the D’Agostino-Pearson normality test. A one-way analysis of variance (ANOVA) followed by a post-hoc Holm-Sidak test was used, whenever normal distribution requirements were met. If the data were not normally distributed, a Kruskal–Wallis one-way ANOVA on
3 RESULTS

3.1 Body Weight, Chow Consumption, and Cardiopulmonary Effects

Hypobaric hypoxia significantly decreased daily Chow consumption (−18%, \( p < 0.001 \)) resulting in a substantial decrease in body weight (−10%, \( p = 0.003 \)) after four weeks compared with mice housed at normobaric ambient pressure (Figure 1B and Table 1). The body weight of mice exposed to hypobaric hypoxia was significantly lower than that of normobaric mice throughout the study. After an initial loss of body weight during week one, hypobaric hypoxia mice gained weight in parallel to the normobaric mice.

Right ventricular size (+70%, \( p < 0.001 \)), wet weights of the lungs (+23%, \( p < 0.001 \)), and hematocrit (+53%, \( p < 0.001 \)) were profoundly increased for all mice exposed to hypobaric hypoxia compared with normobaric mice (Table 1).

These findings are consistent with the expected physiological response to a high-altitude environment with reduced oxygen availability.

3.2 Rectus Femoris Muscle

No significant difference between any of the groups was found for rectus femoris muscle mass. However, a non-significant trend towards decreased muscle mass was found for all mice assigned to hypobaric hypoxia (Table 1).

Rectus femoris whole muscle CSA (−12%, \( p = 0.034 \)) and myofiber CSA (−13%, \( p = 0.029 \)) were significantly reduced in mice exposed to hypobaric hypoxia compared with mice at normobaric ambient pressure. Neither acetazolamide, nor zoledronate affected whole muscle CSA or myofiber CSA compared with hypobaric hypoxia (Table 1).

These findings suggest detrimental effects of hypobaric hypoxia on muscle tissue and affects not only the CSA of the whole muscle but also the CSA of the individual myofibers.

3.3 DXA

Hypobaric hypoxia did not reduce bone mineral density, bone mineral content, or bone length of either femur or tibia compared with normobaric mice (Table 2).

Zoledronate significantly increased femoral and tibial bone mineral density (+6%, \( p = 0.026 \) and +5%, \( p = 0.007 \)), but not bone mineral content, compared to non-treated hypobaric hypoxia mice, respectively. Treatment with acetazolamide did not affect either bone mineral density or bone mineral content compared with mice exposed to hypobaric hypoxia alone (Table 2).

These findings suggest bone mineral density, bone mineral content, and bone length are spared from the detrimental effects of hypobaric hypoxia. In addition, zoledronate was able to increase bone mineral density despite the hypobaric environment, whereas acetazolamide was not.

3.4 μCT

3.4.1 Trabecular Microstructure

At the distal femoral metaphysis, no harmful effects of hypobaric hypoxia were found for bone volume fraction, trabecular number, trabecular spacing, or any other microstructural parameter assessed (Table 3). In contrast, hypobaric hypoxia significantly increased trabecular thickness (+13%, \( p = 0.047 \)) compared with normobaric mice. Acetazolamide significantly decreased trabecular thickness (−12%, \( p = 0.028 \)) compared with non-untreated hypobaric hypoxia mice, as the only observable effect.

At the distal femoral metaphysis, treatment with zoledronate significantly increased bone volume fraction (+64%, \( p = 0.002 \)), trabecular number (−36%, \( p = 0.013 \)), volumetric bone mineral density (+71%, \( p = 0.005 \)), and tissue mineral density (5%, \( p < 0.001 \)) and significantly decreased trabecular spacing (−29%, \( p = 0.027 \)) compared with non-untreated hypobaric hypoxia mice. In addition, the zoledronate induced increase in bone volume...
fraction (+57%, 1 < 0.003 and +49%, 1 < 0.006), volumetric bone mineral density (+63%, 1 < 0.005 and +53%, 1 < 0.019), and tissue mineral density (+4%, 1 < 0.001 and +5%, 1 < 0.001) was significantly above that of both non-treated normobaric mice and acetazolamide-treated mice, respectively.

At the distal femoral epiphysis, no significant detrimental effects of hypobaric hypoxia were found for any trabecular microstructural parameter investigated compared with normobaric mice (Table 3). However, a non-significant trend was found towards decreased bone volume fraction (−15%, 1 = 0.128) in mice exposed to hypobaric hypoxia compared with normobaric mice. Treatment with acetazolamide did not evoke any differences in trabecular microstructure compared with both normobaric and hypobaric mice. Zoledronate significantly increased bone volume fraction (+31%, 1 = 0.003), volumetric bone mineral density (+32%, 1 = 0.001), and tissue mineral density (+3%, 1 < 0.001), and reduced trabecular spacing (−12%, 1 = 0.026) and structure model index compared with non-treated hypobaric mice. In addition, the zoledronate-induced increase in volumetric bone mineral density (+17%, 1 = 0.030) and tissue mineral density (+3%, 1 < 0.001) was significantly higher than in mice treated with acetazolamide.

At L4, hypobaric hypoxia did not have any significantly negative effects on the trabecular microstructure (Figures 3, 4 and Table 3). However, a non-significant trend towards a decreased bone volume fraction (−18%, 1 = 0.124) was found in mice subjected to hypobaric hypoxia compared with normobaric mice. No effect of acetazolamide was found on bone mineral density (+4%, 1 = 0.006), volumetric bone mineral density (+3%, 1 < 0.001), and structure model index compared with non-treated hypobaric mice treated with acetazolamide.

### Table 2

|                | Baseline | Normo | Hypo  | Hypo + AZ | Hypo + ZOL |
|----------------|----------|-------|-------|-----------|------------|
| Femur          |          |       |       |           |            |
| aBMD (mg/cm²)  | 88.8 ± 4.92 | 84.1 ± 6.42 | 83.1 ± 4.78 | 80.7 ± 9.47 | 88.4* ± 7.49 |
| BMC (mg)       | 37.5 ± 2.78 | 36.0 ± 3.67 | 36.3 ± 2.67 | 34.4 ± 4.87 | 37.4 ± 3.90  |
| Bone length (mm) | 16.2 ± 0.44 | 16.5 ± 0.45 | 16.6 ± 0.53 | 16.5 ± 0.59 | 16.5 ± 0.86  |
| Tibia          |          |       |       |           |            |
| aBMD (mg/cm²)  | 73.0 ± 4.09 | 71.4 ± 5.19 | 70.9 ± 5.56 | 67.6 ± 6.04 | 74.4* ± 5.65 |
| BMC (mg)       | 27.1 ± 2.60 | 27.0 ± 2.83 | 26.9 ± 2.76 | 25.0 ± 2.82 | 27.5 ± 2.91  |
| Bone length (mm) | 19.4 ± 0.50 | 19.6 ± 0.40 | 19.4 ± 0.91 | 19.4 ± 0.85 | 19.5 ± 0.50  |

Data are presented as mean ± SD and n = 15–16/group. *p < 0.05 vs. Hypo + AZ.

### Table 3

|                | Baseline | Normo | Hypo  | Hypo + AZ | Hypo + ZOL |
|----------------|----------|-------|-------|-----------|------------|
| Femoral metaphysis |          |       |       |           |            |
| BV/TV (%)       | 13.5 ± 4.78 | 8.87 ± 3.63 | 8.50 ± 4.36 | 9.33 ± 3.33 | 13.9* ± 4.22 |
| Tb.Th (µm)      | 54.7 ± 4.97 | 50.0 ± 6.41 | 56.5* ± 7.33 | 49.5* ± 8.27 | 55.1 ± 5.68  |
| Tb.N (mm⁻¹)     | 3.38 ± 0.86 | 2.53 ± 0.59 | 2.34 ± 0.79 | 2.74 ± 0.73 | 3.18* ± 0.78  |
| Tb.Sp (µm)      | 341 ± 96.1  | 439 ± 97.8  | 512 ± 171   | 418 ± 125   | 362* ± 116   |
| CD (mm⁻¹)       | 185 ± 84.4  | 130 ± 64.5  | 105 ± 68.0  | 145 ± 90.9  | 169 ± 75.3   |
| SmI             | 0.89 ± 0.50 | 1.06 ± 0.46 | 1.09 ± 0.36 | 1.13 ± 0.26 | 0.80 ± 0.37  |
| vBMD (mg/cm³)   | 161 ± 57.7  | 106 ± 46.3  | 101 ± 53.5  | 113 ± 38.5  | 173* ± 59.7  |
| TMD (mg/cm³)    | 991 ± 11.5  | 978 ± 16.6  | 977 ± 24.5  | 973 ± 24.4  | 1021* ± 14.2 |

| Femoral epiphysis |          |       |       |           |            |
| BV/TV (%)       | 34.5 ± 5.55 | 30.0 ± 4.69 | 25.4 ± 5.38 | 27.9 ± 5.09 | 33.2* ± 7.52 |
| Tb.Th (µm)      | 65.4 ± 4.53 | 64.3 ± 4.93 | 66.9 ± 5.82 | 61.0 ± 8.69 | 67.2* ± 4.65 |
| Tb.N (mm⁻¹)     | 7.86 ± 0.77 | 7.03 ± 0.62 | 6.71 ± 0.48 | 6.92 ± 0.86 | 7.44 ± 0.97 |
| Tb.Sp (µm)      | 161 ± 18.3  | 177 ± 15.0  | 188 ± 16.1  | 177 ± 21.0  | 165* ± 19.0  |
| CD (mm⁻¹)       | 301 ± 71.8  | 216 ± 40.4  | 187 ± 60.6  | 245 ± 67.3  | 243 ± 91.6  |
| SmI             | −0.59 ± 0.37 | −0.16 ± 0.30 | −0.01 ± 0.39 | −0.15 ± 0.29 | −0.45* ± 0.43 |
| vBMD (mg/cm³)   | 418 ± 63.8  | 366 ± 54.4  | 311 ± 65.8  | 341 ± 59.4  | 410* ± 88.1  |
| TMD (mg/cm³)    | 1062 ± 9.68 | 1056 ± 10.6 | 1052 ± 16.9 | 1048 ± 18.5 | 1079* ± 10.7 |
| L4              |          |       |       |           |            |
| CD (mm⁻¹)       | 360 ± 88.8  | 286 ± 71.2  | 233 ± 80.2  | 273 ± 80.7  | 282 ± 122   |
| SmI             | −0.27 ± 0.40 | 0.02 ± 0.36 | 0.30 ± 0.39 | 0.14 ± 0.23 | −0.16* ± 0.49 |
| vBMD (mg/cm³)   | 303 ± 49.8  | 252 ± 42.3  | 207 ± 55.3  | 236 ± 48.2  | 293* ± 75.1  |
| TMD (mg/cm³)    | 968 ± 16.5  | 952 ± 12.3  | 944 ± 21.6  | 951 ± 16.5  | 981* ± 18.4  |

Bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), trabecular number (Tb.N), connectivity density (CD), structure model index (SmI), volumetric bone mineral density (vBMD), and tissue mineral density (TMD). All data were analyzed using a one-way ANOVA, except for femoral metaphyseal Tb.Sp, CD, vBMD, and TMD, and femoral epiphyseal Tb.Sp, CD, SmI, and TMD, and L4 CD where the non-parametric Kruskal-Wallis test was used. Data are presented as mean ± SD and n = 15–16/group. *p < 0.05 vs. Normo, †p < 0.05 vs. Hypo, and ‡p < 0.05 vs. Hypo + AZ.
any trabecular microstructural parameter investigated compared with both normobaric and hypobaric mice. In contrast, treatment with zoledronate significantly increased bone volume fraction (+40%, \( p = 0.001 \)), volumetric bone mineral density (+32%, \( p = 0.001 \)), and tissue mineral density (+3%, \( p < 0.001 \)) compared with non-treated mice exposed to hypobaric hypoxia.

Overall, these findings suggest few negative effects of hypobaric hypoxia on the vertebral trabecular microstructure. Acetazolamide had no positive effects, while the anti-resorptive effect of zoledronate was apparent despite concomitant exposure to hypobaric hypoxia.

3.4.2 Cortical Morphology

At the femoral mid-diaphysis, exposure to hypobaric hypoxia significantly decreased cortical thickness (−10%, \( p = 0.040 \)) and increased marrow area (+15%, \( p = 0.043 \)) compared with normobaric mice (Figures 4E, H). Treatment with acetazolamide did not affect any cortical bone parameter assessed compared with both normobaric and hypobaric mice. Zoledronate significantly increased cortical thickness (+13%, \( p < 0.001 \)) and reduced both tissue area (−11%, \( p = 0.007 \)) and marrow area (−21%, \( p < 0.001 \)) compared with non-treated mice exposed to hypobaric hypoxia. The cortical thickness of zoledronate-treated mice (+8%, \( p = 0.017 \)) was also significantly above that of mice treated with acetazolamide.

These findings suggest that the detrimental effects of hypobaric hypoxia on cortical thickness develop due to an increased endocortical bone resorption.

3.5 Bone Strength

There was no significant difference in bone strength at the femoral mid-diaphysis or femoral neck between any of the groups (Table 4).

3.6 Dynamic Bone Histomorphometry and Bone Cells

3.6.1 Trabecular Bone

At the distal femoral metaphysis, hypobaric hypoxia significantly increased osteoid-covered (+49%, \( p = 0.016 \)) and osteoblast-covered surfaces (+69%, \( p = 0.021 \)) compared with normobaric mice, while mineralizing surface, mineral apposition rate, and bone formation rate were not altered (Figure 5). Treatment with acetazolamide did not affect any of the dynamic bone histomorphometric parameters, the amount of osteoid-, osteoblast-, or osteoclast-covered surfaces compared with both normobaric and hypobaric mice.

Zoledronate significantly reduced mineralizing surface (−55%, \( p < 0.001 \) and −54%, \( p < 0.001 \)), mineral apposition rate (−39%, \( p = 0.025 \) and −43%, \( p < 0.001 \)), bone formation rate (−68%, \( p < 0.001 \) and −70%, \( p < 0.001 \)), osteoid-covered surfaces (−74%, \( p < 0.001 \) and −82%, \( p < 0.001 \)), and osteoblast-covered surfaces (−73%, \( p = 0.017 \) and −84%, \( p < 0.001 \)) compared with normobaric and hypobaric mice, respectively. In addition, zoledronate significantly decreased all these parameters compared with mice treated with acetazolamide.

These findings suggest limited effects of exposure to hypobaric hypoxia and treatment with acetazolamide on histological indices of bone formation. In contrast, treatment with zoledronate inhibited bone formation and bone resorption.

3.6.2 Cortical Bone

At the femoral mid-diaphyseal periosteal surface, no significant differences were found between any of the groups (Table 5).

At the femoral mid-diaphyseal endocortical surface, treatment with zoledronate significantly reduced mineralizing surface (−48%, \( p < 0.001 \)), mineral apposition rate (−62%, \( p = 0.011 \)), and bone formation rate (−69%, \( p = 0.06 \)) compared with non-treated hypobaric mice (Table 5). The zoledronate-induced reduction in mineralizing surface (−42%, \( p = 0.004 \) and −35%, \( p = 0.042 \)) was significantly lower compared with both normobaric mice and hypobaric mice treated with acetazolamide, respectively.

These findings suggest that the detrimental effects of exposure to hypobaric hypoxia on cortical thickness materialized earlier than the inter-labelling period of fluorochrome labels (one and two weeks before the study ended). Acetazolamide had no negative effects, while treatment with zoledronate substantially reduced endocortical bone formation.

4 DISCUSSION

Exposure to high altitude is extremely challenging to most organ systems, and the ensuing cardiopulmonary adaption is vital for acclimatization. We have recently demonstrated that exposure to simulated high altitude impairs bone integrity...
suggesting acclimatization to high altitude exposure has detrimental effects on the musculoskeletal system (5). In the present study, mice were exposed to simulated high altitude (5,500 m) for four weeks and were treated with either acetazolamide or zoledronate.

The cardiopulmonary response to decreased barometric pressure was established by increased lung weight and right ventricle hypertrophy. As expected, lung weight substantially increased and right ventricle underwent hypertrophy in all mice exposed to simulated high altitude. These findings were accompanied by a pronounced increase in hematocrit in all groups exposed to hypobaric hypoxia and are in accordance with previous studies in rodents (4, 5, 35) and humans (24, 26, 36, 37).

We have previously demonstrated that mice exposed to simulated high altitude primarily have deteriorated cortical bone, while trabecular bone is affected less or even completely spared from any detrimental effects (5). The present study confirms that decreased barometric pressure have a negative impact on cortical bone – specifically reduced cortical thickness and increased cortical marrow area. The increased marrow area and maintained tissue area indicate that the hypoxia-induced bone resorption was located mainly at the endocortical surface. Although speculative, the observed increased marrow area and reduced cortical thickness may suggest that the hypoxia-induced enhanced erythropoiesis, seen as a substantial increased hematocrit, occurs at the expense of the adjacent cortical bone. This view is supported by Oikonomidou et al. who demonstrated a substantially reduced cortical thickness in a mouse model of polycythemia vera, and by others who showed that increased levels of erythropoietin (EPO) – the primary hormone

**TABLE 4** | Maximum bone strength at femoral mid-diaphysis, femoral neck, and L4 of mice housed at normobaric ambient pressure (Normo) or hypobaric pressure (Hypo) at 500 mbar for four weeks and treated with acetazolamide (AZ) or zoledronate (ZOL).

|          | Baseline | Normo | Hypo | Hypo + AZ | Hypo + ZOL |
|----------|----------|-------|------|----------|-----------|
| Femoral mid-diaphysis (N) | 27.5 ± 3.22 | 25.9 ± 4.17 | 26.9 ± 2.89 | 25.5 ± 4.73 | 26.7 ± 4.03 |
| Femoral neck (N) | 23.6 ± 3.26 | 23.3 ± 3.19 | 21.9 ± 2.52 | 20.2 ± 4.18 | 22.3 ± 3.20 |
| L4 (N) | 29.8 ± 6.89 | 29.2 ± 6.80 | 25.6 ± 10.1 | 27.9 ± 9.24 | 34.1 ± 13.8 |

All data were analyzed using a one-way ANOVA, except for femoral neck strength where the non-parametric Kruskal–Wallis test was used. Data are presented as mean ± SD and n = 15–16/group. *p < 0.05, **p < 0.01, and ***p < 0.001.
FIGURE 5 | Distal femoral trabecular bone parameters determined by dynamic bone histomorphometry (A–C) and osteoid (D) and bone cells quantification (E, F) of mice housed at normobaric ambient pressure (Normo) or hypobaric pressure (Hypo) at 500 mbar for four weeks and treated with acetazolamide (AZ) or zoledronate (ZOL). All data were analyzed using a one-way ANOVA, except for mineralizing surface and mineral apposition rate where the non-parametric Kruskal-Wallis test were used. Data are presented as mean ± SD and n = 15–16/group. *p < 0.05, ***p < 0.001, and ****p < 0.0001.
TABLE 5 | Mid-diaphyseal femoral cortical bone parameters determined by dynamic bone histomorphometry of mice housed at normobaric ambient pressure (Normo) or hypobaric pressure (Hypo) at 500 mbar for four weeks and treated with acetazolamide (AZ) or zoledronate (ZOL). Periosteal bone surface (Ps), endocortical bone surface (Ec), mineralizing surface/bone surface (MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS).

|                  | Normo | Hypo | Hypo + AZ | Hypo + ZOL |
|------------------|-------|------|-----------|------------|
| Ps.MS/BS (%)     | 19.3 ± 11.3 | 23.7 ± 17.5 | 13.3 ± 8.80 | 17.1 ± 9.53 |
| Ps.MAR (µm/day)  | 0.18 ± 0.28 | 0.43 ± 0.45 | 0.30 ± 0.44 | 0.36 ± 0.43 |
| Ps.BFR/BS (µm²/µm²/day) | 0.04 ± 0.06 | 0.16 ± 0.18 | 0.06 ± 0.09 | 0.08 ± 0.10 |
| Ec.MS/BS (%)     | 26.5 ± 6.98 | 29.6 ± 7.20 | 23.4 ± 9.50 | 15.0 ± 10.8 |
| Ec.MAR (µm/day)  | 0.99 ± 0.78 | 1.17 ± 0.58 | 0.82 ± 0.65 | 0.45 ± 0.57 |
| Ec.BFR/BS (µm³/µm³/day) | 0.28 ± 0.24 | 0.35 ± 0.19 | 0.45 ± 0.57 | 0.11 ± 0.16 |

All data were analyzed using a one-way ANOVA, except for Ps.MAR and Ec.MAR where the non-parametric Kruskal-Wallis test was used. Data are presented as mean ± SD and n = 15–16/group. *p < 0.05 vs. Normo, †p < 0.05 vs. Hypo, and ‡p < 0.05 vs. Hypo + AZ.

Responsible for red blood cell production – are associated with loss of bone (38, 39).

Surprisingly, the loss of cortical thickness manifested without decreased bone mineral density, bone strength, or endocortical indices of bone formation, as we have previously demonstrated in mice exposed to hypobaric hypoxia (5). In contrast to our previous study of mice exposed to simulated high altitude, the mice used in the present study were younger. Age differences between the mice from the two studies might explain some of the disparity in the present study were younger. Age differences between the mice from the two studies might explain some of the disparity in the present study were younger. As expected, zoledronate also decreased bone mineral density and cortical thickness increased and the marrow area decreased compared with non-treated mice allocated to hypobaric hypoxia. This might reflect that endocortical preservation has less impact on the mid-diaphyseal bone strength than periosteal bone preservation (46). Moreover, the increased areal bone mineral density reflects the bone density of the whole femur and is therefore influenced by the increased trabecular bone volume fraction at the distal metaphysis and epiphysis. However, these skeletal sites do not contribute to the mid-diaphyseal bone strength. At L4, zoledronate increased the trabecular bone volume fraction compared with non-treated mice exposed to hypobaric hypoxia, but this finding was not accompanied by an increased bone strength. However, large variations in bone strength at L4 might have masked the effect and contributed to the discordance between microstructure and bone strength. As expected, zoledronate also decreased mineralizing surface, mineral apposition rate, bone formation rate, osteoid-covered surfaces, and osteoblast-covered surfaces. The profound impact of zoledronate on histological indices of bone formation is in agreement with previous studies by us (47, 48) and others (49, 50) and highlights its potent anti-resorptive effect. The present findings provide the first preclinical support for further clinical studies of zoledronate in the prevention of altitude-induced bone loss.

The study underlines the negative effects of exposure to hypobaric hypoxia on body weight and appetite. All mice exposed to simulated high altitude lost weight during the first week of the study and thereafter gained weight in parallel to normobaric mice. However, their food caloric intake was consistently lower throughout the study.

High altitude-induced anorexia and weight loss have been demonstrated in several studies in rodents and mountaineers...
Malnutrition and reduced daily caloric intake are associated with reduced bone mineral density and osteoporosis (55–57). The negative effects of simulated high altitude might, therefore, at least to some degree, be a result of the reduced caloric intake (54).

The study has several limitations. Acetazolamide was administered in the drinking water, and the target dose of 50 mg/kg/day was ensured by adjusting the concentration weekly. Weekly differences in water consumption throughout the study made it difficult to ensure the target dose was met throughout the study. The actual average acetazolamide dose (62 ± 28 mg/kg/day) was slightly above the target dose, and a rather large weekly dose dispersion was observed. The dose of acetazolamide was based on a study in rats using a dose of 50 mg/kg/day (intrapерitoneal injected) and corresponded approximately to the human equivalent dose used to prevent AMS in adults (8, 58). Although challenging, we administered acetazolamide in the drinking water in order to more closely resemble how the drug is administered in mountaineers as prophylaxis for AMS and to reduce the time spent outside the hypobaric chambers as intraperitoneal injections would require daily disruption of the hypobaric environment. Moreover, sucrose was only added to the drinking water of acetazolamide-treated animals in order to encourage consumption and mask any unpleasant undertaste. However, their body weight was not affected by access to additional calories in the water compared with mice receiving tap water without added sucrose.

Another limitation is that hypobaric hypoxia was not maintained uninterrupted as is the case for expeditions to high altitude mountains. However, injections of fluorochromes to assess bone formation, cleaning and resupplying of chow and water, and weighing were performed once weekly to limit the time spent outside the hypobaric environment.

The present study investigated 16-week-old female mice only. Therefore, it cannot be ruled out that the effect of exposure to hypobaric hypoxia or the treatment response to acetazolamide and zoledronate are sex or age-dependent. However, we have recently comprehensively reviewed the effect of hypobaric hypoxia in rodents and real-world altitude exposure in mountaineers and found no indication that the associated detrimental skeletal effects are age or sex specific (54).

Thus, the treatment with acetazolamide did not prevent cortical bone loss, whereas treatment with zoledronate did. These findings provide initial preclinical support for clinical studies of zoledronate as a potential pharmacological countermeasure against bone loss from exposure to high altitude.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by the Danish Animal Experiment Inspectorate (2018–15–0201–01436).

AUTHOR CONTRIBUTIONS

Study design: MB, US, JT, and AB. Study conduct: MB and AB. Data collection, data analysis, and interpretation: MB, JT, and AB. Manuscript draft: MB. Figures and graphical design: MB. Manuscript revision: MB, US, JT, and AB. All authors contributed to the article and approved the submitted version.

FUNDING

The study was kindly supported by Health Aarhus University, The A.P. Møller Foundation for the Advancement of Medical Science, The Frimodt-Heineke Foundation, Torben and Alice Frimodt’s Foundation, and Aase and Ejnar Danielsen’s Foundation. The funding bodies did not have any role in the study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; or in the decision to submit the article for publication.

ACKNOWLEDGMENTS

The authors are thankful for the excellent technical assistance of Jytte Utoft. The authors thank Visiopharm for their contribution to the stereology software system. The µCT system was donated by the VELUX Foundation.

REFERENCES

1. Imray C, Wright A, Subudhi A, Roach R. Acute Mountain Sickness: Pathophysiology, Prevention, and Treatment. Prog Cardiovasc Di (2010) 52:467–84. doi: 10.1016/j.pcd.2010.02.003
2. Hackett PH, Roach RC. High Altitude Pulmonary Edema. J Wilderness Med (1990) 1:3–26. doi: 10.1580/0953-9859-1.1.3
3. Hackett PH, Roach RC. High Altitude Cerebral Edema. High Alt Med Biol (2004) 5:136–46. doi: 10.1089/1527029041352054
4. Bozziini C, Olivera MI, Huygens P, Alippi RM, Bozziini CE. Long-Term Exposure to Hypobaric Hypoxia in Rat Affects Femur Cross-Sectional Geometry and Bone Tissue Material Properties. Ann Anat (2009) 191:212–7. doi: 10.1016/j.aanat.2008.11.002
5. Brent MB, Emmanuel T, Simonsen U, Brøel A, Thomsen JS. Hypobaric Hypoxia Deteriorates Bone Mass and Strength in Mice. Bone (2022) 154:116203. doi: 10.1016/j.bone.2021.116203
6. Tanaka H, Minowa K, Satoh T, Koike T. Bone Atrophy at High Altitude. J Bone Miner Metab (1999) 17:467–72. doi: 10.1007/s007740050243
7. Hackett PH, Roach RC. High-Altitude Illness. N Engl J Med (2001) 345:107–14. doi: 10.1056/NEJM200107123450206
8. Luks AM, Auerbach PS, Freer L, Grissom CK, Keyes LE, McIntosh SE, et al. Wilderness Medical Society Clinical Practice Guidelines for the Prevention
48. Wendelboe MH, Thomsen JS, Henriksen K, Vegger JB, Brüel A. Zoledronate Prevents Lactation Induced Bone Loss and Results in Additional Post-Lactation Bone Mass in Mice. Bone (2016) 87:27–36. doi: 10.1016/j.bone.2016.03.012
49. Shapiro JR, Boskey AL, Doty SB, Lukashova L, Blue ME. Zoledronic Acid Improves Bone Histomorphometry in a Murine Model of Rett Syndrome. Bone (2017) 99:1–7. doi: 10.1016/j.bone.2017.03.040
50. Pataki A, Muller K, Green JR, Ma YF, Li QN, Jee WSS. Erratum: Effects of Short-Term Treatment With the Bisphosphonates Zolendronate and Pamidronate on the Rat Bone: A Comparative Histomorphometric Study on the Cancellous Bone Formed Before, During, and After Treatment. Anatomical Rec (1997) 249:458–68. doi: 10.1002/(SICI)1097-0185(199712)249:4. Wiley-Liss, Inc (1998).
51. Elia R, Elgoyhen AB, Bugallo G, Río ME, Bozzini CE. Effect of Acute Exposure to Reduced Atmospheric Pressures on Body Weight, Food Intake and Body Composition of Growing Rats. Acta Physiol Pharmacol Latinoam (1985) 35:311–8.
52. Vats P, Singh VK, Singh SN, Singh SB. High Altitude Induced Anorexia: Effect of Changes in Leptin and Oxidative Stress Levels. Nutr Neurosci (2007) 10:243–9. doi: 10.1080/10284150701722299
53. Hannon JP, Krabill LF, Wooldridge TA, Schnakenberg DD. Effects of High Altitude and Hypophagia on Mineral Metabolism of Rats. J Nutr (1975) 105:278–87. doi: 10.1093/jn/105.3.278
54. Brent MB. A Review of the Skeletal Effects of Exposure to High Altitude and Potential Mechanisms for Hypobaric Hypoxia-Induced Bone Loss. Bone (2022) 154:116258. doi: 10.1016/j.bone.2021.116258
55. Devin MJ, Cloutier AM, Thomas NA, Panus DA, Lotinun S, Pinz I, et al. Caloric Restriction Leads to High Marrow Adiposity and Low Bone Mass in Growing Mice. J Bone Miner Res (2010) 25:2078–88. doi: 10.1002/jbmr.82
56. Villareal DT, Fontana L, Weiss EP, Racette SB, Steger-May K, Schechtman KB, et al. Bone Mineral Density Response to Caloric Restriction-Induced Weight Loss or Exercise-Induced Weight Loss: A Randomized Controlled Trial. Arch Intern Med (2006) 166:2502–10. doi: 10.1001/archinte.166.22.2502
57. Jacongeli F, Zoli A, Taranto A, Staar Mezzasalma F, Ficoneri C, Pierangeli S, et al. Osteoporosis and Anorexia Nervosa: Relative Role of Endocrine Alterations and Malnutrition. Eat Weight Disord (2002) 7:190–5. doi: 10.1007/BF03327456
58. Nair A, Jacob S. A Simple Practice Guide for Dose Conversion Between Animals and Human. J Basic Clin Pharm (2016) 7:27. doi: 10.4103/0976-0105.177703

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Brent, Simonsen, Thomsen and Brüel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.